AR104362A1 - Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios - Google Patents
Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatoriosInfo
- Publication number
- AR104362A1 AR104362A1 ARP160101128A ARP160101128A AR104362A1 AR 104362 A1 AR104362 A1 AR 104362A1 AR P160101128 A ARP160101128 A AR P160101128A AR P160101128 A ARP160101128 A AR P160101128A AR 104362 A1 AR104362 A1 AR 104362A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- optionally substituted
- halo
- alkyl
- alkoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) en donde LA es O, o NH; y CyA es heterocicloalquilo monocíclico de 4 - 6 miembros que comprende uno o dos átomos de O; cada RA se selecciona de manera independiente de halo y alquilo C₁₋₃; el subíndice n es 0, 1 ó 2; R¹ es H o alquilo C₁₋₃; R² es H, -OH o alcoxi C₁₋₃; R³ es H o alcoxi C₁₋₃; R⁴ es H, -CN, -OH, -O-S(=O)₂-alquilo C₁₋₄ opcionalmente sustituido con uno o varios halo seleccionados de manera independiente, o -L¹-W¹-G¹; L¹ es un enlace directo, -O-, -S-, -SO₂-, -C(=O)NR⁵ᵃ-, -NR⁵ᵇC(=O)-, o -NR⁵ᶜ-; R⁵ᵃ, R⁵ᵇ y R⁵ᶜ son de manera independiente H o alquilo C₁₋₄; W¹ es un enlace directo o alquileno C₁₋₂ opcionalmente sustituido con uno o varios halo seleccionados de manera independiente; G¹ es cicloalquilo C₃₋₆ opcionalmente sustituido con uno o varios halo seleccionados de manera independiente, heteroarilo de 5 - 6 miembros que comprende uno a cuatro heteroátomos seleccionados de manera independiente de N, O y S, donde el heteroarilo está opcionalmente sustituido con uno o varios alquilo C₁₋₄ seleccionados de manera independiente, heterocicloalquenilo de 5 - 7 miembros que comprende un enlace doble, y uno a tres heteroátomos seleccionados de manera independiente de N, O y S, donde heterocicloalquenilo está opcionalmente sustituido con uno o varios R⁶ seleccionados de manera independiente, heterocicloalquilo monocíclico o espiro bicíclico de 4 - 8 miembros que comprende uno a tres heteroátomos seleccionados de manera independiente de N, O y S, donde heterocicloalquilo está opcionalmente sustituido con uno o varios R⁶ seleccionados de manera independiente, heterocicloalquilo monocíclico de 4 - 6 miembros que comprende uno a tres heteroátomos seleccionados de manera independiente de N, O y S, fusionado a uno o dos fenilos, alquilo C₁₋₄ opcionalmente sustituido con uno o varios halo, -NR⁷ᵃR⁷ᵇ o alcoxi C₁₋₄ seleccionados de manera independiente, donde alcoxi está opcionalmente sustituido con uno o varios halo seleccionados de manera independiente, o fenilo opcionalmente sustituido con uno o varios halo o alcoxi C₁₋₄ seleccionados de manera independiente, donde alcoxi está opcionalmente sustituido con uno o varios halo seleccionados de manera independiente; R⁶ es halo, =O, -CN, -OH, -C(=O)-alcoxi C₁₋₄ opcionalmente sustituido con uno o varios halo seleccionados de manera independiente, -C(=O)-cicloalquilo C₃₋₄, -S(=O)₂-alquilo C₁₋₄, alquilo C₁₋₄ opcionalmente sustituido con uno o varios alcoxi C₁₋₃, halo u -OH seleccionados de manera independiente, alcoxi C₁₋₄, fenilo opcionalmente sustituido con uno o varios halo seleccionados de manera independiente, -C(=O)-heterocicloalquilo monocíclico de 4 - 6 miembros que comprende uno a tres heteroátomos seleccionados de manera independiente de N, O y S, -C(=O)NR⁸ᵃR⁸ᵇ, o heteroarilo de 5 - 7 miembros que comprende uno a cuatro heteroátomos seleccionados de manera independiente de N, O y S, donde el heteroarilo está opcionalmente sustituido con uno o varios alquilo C₁₋₄ seleccionados de manera independiente; cada R⁷ᵃ y R⁷ᵇ es de manera independiente H o alquilo C₁₋₄; y cada R⁸ᵃ y R⁸ᵇ es de manera independiente H o alquilo C₁₋₃; o una sal farmacéuticamente aceptable, o un solvato, o una sal farmacéuticamente aceptable de un solvato del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506894.3A GB201506894D0 (en) | 2015-04-23 | 2015-04-23 | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104362A1 true AR104362A1 (es) | 2017-07-12 |
Family
ID=53488521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101128A AR104362A1 (es) | 2015-04-23 | 2016-04-22 | Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10568879B2 (es) |
| EP (1) | EP3286191B1 (es) |
| JP (1) | JP6777652B2 (es) |
| KR (1) | KR20170139142A (es) |
| CN (1) | CN107531703B (es) |
| AR (1) | AR104362A1 (es) |
| AU (1) | AU2016251517A1 (es) |
| BR (1) | BR112017022008A2 (es) |
| CA (1) | CA2983342A1 (es) |
| CO (1) | CO2017011093A2 (es) |
| GB (1) | GB201506894D0 (es) |
| IL (1) | IL255109A0 (es) |
| MX (1) | MX2017013382A (es) |
| PH (1) | PH12017501911A1 (es) |
| RU (1) | RU2017134551A (es) |
| SG (1) | SG11201708671RA (es) |
| TW (1) | TW201702243A (es) |
| WO (1) | WO2016169911A1 (es) |
| ZA (1) | ZA201706674B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3403649A1 (en) * | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
| CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
| EP3665156A4 (en) | 2017-08-09 | 2021-04-28 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS, AND PROCEDURES |
| BR112020008425A2 (pt) * | 2017-11-15 | 2020-11-17 | Galapagos N.V. | compostos e composições farmacêuticas dos mesmos para uso no tratamento de doenças fibróticas |
| WO2020007342A1 (zh) * | 2018-07-06 | 2020-01-09 | 中国科学院上海药物研究所 | 联苯磷酸酯类化合物作为gpr84拮抗剂的应用 |
| EP3924341A4 (en) * | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| CN113518618A (zh) * | 2019-02-13 | 2021-10-19 | 戴纳立制药公司 | 化合物、组合物及方法 |
| CN115135656A (zh) * | 2019-12-19 | 2022-09-30 | 拜耳公司 | 呋喃并吲唑衍生物 |
| WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
| CA3211437A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| WO2022218372A1 (zh) * | 2021-04-14 | 2022-10-20 | 武汉人福创新药物研发中心有限公司 | 一种二氢嘧啶并异喹啉酮类衍生物及用途 |
| EP4330260A1 (en) | 2021-04-29 | 2024-03-06 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| WO2022263676A1 (en) | 2021-06-18 | 2022-12-22 | University Of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
| CN115611944A (zh) | 2021-07-15 | 2023-01-17 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0926148A1 (en) * | 1997-12-23 | 1999-06-30 | Applied Research Systems Ars Holding N.V. | Benzo (C)quinolizine derivatives, their preparation and use as 5-alphareductases inhibitors |
| WO2005050225A2 (en) * | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
| US8691498B2 (en) | 2005-09-02 | 2014-04-08 | Arena Pharmaceuticals, Inc. | Methods of screening for a compound that reduces atherogenesis |
| JP2013537203A (ja) | 2010-09-20 | 2013-09-30 | グラクソ グループ リミテッド | 三環式化合物、製造方法、およびそれらの使用 |
| AR089284A1 (es) * | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| CN104870445B (zh) | 2012-12-20 | 2017-09-15 | 加拉帕戈斯股份有限公司 | 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂) |
| GB201411241D0 (en) * | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2015
- 2015-04-23 GB GBGB1506894.3A patent/GB201506894D0/en not_active Ceased
-
2016
- 2016-04-19 RU RU2017134551A patent/RU2017134551A/ru not_active Application Discontinuation
- 2016-04-19 BR BR112017022008-3A patent/BR112017022008A2/pt not_active Application Discontinuation
- 2016-04-19 EP EP16720370.2A patent/EP3286191B1/en active Active
- 2016-04-19 SG SG11201708671RA patent/SG11201708671RA/en unknown
- 2016-04-19 WO PCT/EP2016/058607 patent/WO2016169911A1/en active Application Filing
- 2016-04-19 US US15/568,275 patent/US10568879B2/en active Active
- 2016-04-19 AU AU2016251517A patent/AU2016251517A1/en not_active Abandoned
- 2016-04-19 KR KR1020177033832A patent/KR20170139142A/ko unknown
- 2016-04-19 MX MX2017013382A patent/MX2017013382A/es unknown
- 2016-04-19 CN CN201680023369.1A patent/CN107531703B/zh active Active
- 2016-04-19 JP JP2017555303A patent/JP6777652B2/ja active Active
- 2016-04-19 CA CA2983342A patent/CA2983342A1/en not_active Abandoned
- 2016-04-21 TW TW105112490A patent/TW201702243A/zh unknown
- 2016-04-22 AR ARP160101128A patent/AR104362A1/es unknown
-
2017
- 2017-10-04 ZA ZA2017/06674A patent/ZA201706674B/en unknown
- 2017-10-18 IL IL255109A patent/IL255109A0/en unknown
- 2017-10-19 PH PH12017501911A patent/PH12017501911A1/en unknown
- 2017-10-30 CO CONC2017/0011093A patent/CO2017011093A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018513180A (ja) | 2018-05-24 |
| CN107531703B (zh) | 2020-09-01 |
| SG11201708671RA (en) | 2017-11-29 |
| MX2017013382A (es) | 2017-12-07 |
| CA2983342A1 (en) | 2016-10-27 |
| AU2016251517A1 (en) | 2017-10-26 |
| PH12017501911A1 (en) | 2018-03-05 |
| IL255109A0 (en) | 2017-12-31 |
| RU2017134551A (ru) | 2019-04-04 |
| US20190062325A1 (en) | 2019-02-28 |
| CN107531703A (zh) | 2018-01-02 |
| US10568879B2 (en) | 2020-02-25 |
| ZA201706674B (en) | 2019-07-31 |
| EP3286191B1 (en) | 2020-07-29 |
| WO2016169911A1 (en) | 2016-10-27 |
| BR112017022008A2 (pt) | 2018-07-03 |
| GB201506894D0 (en) | 2015-06-10 |
| KR20170139142A (ko) | 2017-12-18 |
| JP6777652B2 (ja) | 2020-10-28 |
| TW201702243A (zh) | 2017-01-16 |
| CO2017011093A2 (es) | 2018-01-31 |
| EP3286191A1 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104362A1 (es) | Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR099111A1 (es) | Derivados de azepano y su uso para tratar infecciones de hepatitis b | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100244A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR089284A1 (es) | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR107428A1 (es) | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC | |
| AR109437A1 (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
| AR093123A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina | |
| AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |